Skip navigation |

Abbot's ABT 450

Abbot has non-nucleoside polymerase inhibitors (ABT-333 and ABT-072) and an NS5A inhibitor (ABT-267) in its pipeline. Abbott has established partnership with Enanta Pharmaceuticals for protease inhibitor ABT-450 and ABT-450 containing regimens.

Over 79% of previously untreated and null-responder patients with genotype 1a hepatitis C achieved a sustained virological response 12 weeks after completing treatment with an interferon-free combination of 2 or 3 direct-acting antiviral agents developed by Abbott (ABT-450, ABT-267, and/or ABT-333), investigators reported at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) in November in Boston.

In the group receiving all 3 drugs plus ribavirin, 96% of patients achieved a sustained virological response 12 weeks after the end of treatment (known as SVR12), while only 2 out of 148 patients with HCV genotype 1b receiving any of the drug combinations tested in the study failed to achieve SVR12.

abbot drugs.png

All of the Phase II studies of Abbott's HCV lead candidate ABT-450 look very promising with the higher SVR rates, shorter duration of treatment, interferon-free regimen, and controlled adverse events. Particularly results from the Aviator study have set a high bar for the rest of the HCV companies. Based on the promising SVR12 results from Aviator study, in October 2012, Abbott has posted a Phase III hepatitis C study (Turquoise-II) to evaluate the safety and efficacy of ABT-450, ritonavir, and ABT-267 (ABT-450/r/ABT-267) as well as ABT-333 co-administered with RBV in adults with Genotype 1 HCV infection and cirrhosis. The Turquoise Phase III study hasn't started enrolling patients.